Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:03:31 23/06/2025 BST			5-day change	1st Jan Change
510.90 ^USD	+0.23%		-1.73%	-27.89%

11:00am	European Medicines Regulator Recommends Approval of Alvotech's Eylea Biosimilar AVT06	MT
06-20	Global markets live: Accenture, Amazon, Google, Tesla, UniCredit…

TD Cowen Raises Price Target on Regeneron Pharmaceuticals to $1,230 From $1,200

Published on 01/08/2024 at 19:40, updated on 01/08/2024 at 19:51

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

European Medicines Regulator Recommends Approval of Alvotech's Eylea Biosimilar AVT06	11:00am	MT
Global markets live: Accenture, Amazon, Google, Tesla, UniCredit…	06-20
Sector Update: Health Care Stocks Rise Premarket Friday	06-20	MT
Sector Update: Health Care	06-20	MT
Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease	06-20	MT
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease	06-20	DJ
Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent for the Treatment of Adult Patients with Bullous Pemphigoid	06-20	CI
Sanofi and Regeneron's Dupixent Approves in the US as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid	06-20	CI
Scholar Rock's drug helps Zepbound patients retain more muscle in trial	06-18	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	06-17	MT
Sector Update: Health Care Stocks Fall in Afternoon Trading	06-17	MT
Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe	06-17	MT
Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe	06-17	MT
Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln	06-16	RE
European Equities Close Mostly Higher in Monday Trading; Renault CEO to Step Down, Expected to Join Kering	06-16	MT
Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million	06-16	MT
Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial	06-16	MT
Sanofi And Regeneron Pharmaceuticals, Inc. Announce Dupixent's Superiority Over Xolair In Phase 4 Study	06-15	CI
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Everest Phase 4 Trial in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps	06-15	CI
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm	06-13	RE
23Andme Reaches Agreement For Sale Of Business To TTAM Research Institute	06-13	RE
23andMe's founder Anne Wojcicki wins bid for DNA testing firm	06-13	RE
Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10:40 AM	06-12
US states sue 23andMe to protect customers' private data	06-10	RE

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

REGN: Dynamic Chart

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.

Employees

15,158

Sector

Biotechnology & Medical Research

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company